Evaluation of the efficacy and safety of luseogliflozin and changes in QO

Not Applicable

• Conditions: Type 2 diabetes mellitus

• Registration Number: JPRN-UMIN000023035
• Lead Sponsor: The Institute for Adult Diseases, Asahi Life Foundation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-07-11
• Study Completion: 2018-02-13
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with diabetes other than type 2 diabetes 2) Patients with a history of cardiovascular events such as cerebral infarction and myocardial infarction. 3) Patients with serious renal or hepatic dysfunction 4) Patients with malignant tumors (those who have a history of malignant tumors but are currently receiving no treatment and had no recurrence, and those considered unlikely to have any recurrence during the study period are eligible for the study). 5) Patients with repeated genital or urinary tract infections 6) Patients with eGFR <=30 mL/min/1.73 m2 7) Patients with BMI <=20 8) Patients for whom dosage and administration of concomitant antidiabetic drugs have been changed within the 12 weeks prior to the start of administration of the study drug. 9) Patients who have administered a SGLT2 inhibitor within 6 months prior to the start of administration of the study drug 10) Patients whose answers to the questionnaire at week 0 were not collected before the start of administration. 11) Patients deemed unsuitable for participation in the study by the investigator or sub-investigator due to other reasons.

Study & Design

• Study Type: Interventional
• Study Design: Not specified